Verified peer comparison

REGN vs ABBV

Regeneron Pharmaceuticals, Inc. compared with AbbVie Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

REGN

Regeneron Pharmaceuticals, Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

ABBV

AbbVie Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

REGN: Biotechnology

ABBV: Biotechnology

Upside lens

REGN: New indications, age groups and geographies can extend a broad type-2 inflammation franchise. Longer dosing intervals can support retinal share and physician adoption despite biosimilar entry. Bispecific antibodies, immunology assets and genetic medicines offer multiple routes to portfolio expansion.

ABBV: Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology. Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

Risk lens

REGN: Biosimilars and rival long-duration therapies can erode EYLEA volume, pricing and share. Profit-sharing and dependence on collaborators shape the cash economics of major products. Late-stage oncology and immunology programs may fail to show sufficient efficacy or safety.

ABBV: Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition. Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand. U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.

Verified sources

Regeneron Reports First Quarter 2026 Financial and Operating ResultsRegeneron Pharmaceuticals, Inc. · earningsVerified